Icahn School of Medicine at Mount Sinai (ISMMS) Centers are hubs for collaborative research and patient care. Using cutting-edge technologies and approaches, our scientists and clinicians are breaking through the current boundaries of biomedicine. Many ISMMS research launch clinical trials through their Centers that our patient populations participate in.
The Mount Sinai Adolescent Health Center offers a comprehensive, interdisciplinary and integrated model of medical, mental health, sexual and reproductive health, and dental services, plus prevention education and services for healthy lifestyles.
Upon opening its doors in 1968, the Mount Sinai Adolescent Health Center became the first health service in New York created specifically for adolescents. Today it is the largest, most comprehensive adolescent center in the country, providing high quality care to more than 11,000 disadvantaged young people ages 10 to 24 in New York City. Most lack insurance or the ability to pay for services despite being of highest need.
Our physicians, nurse practitioners, physician assistants, psychiatrists, psychologists, social workers, nutritionists, and other professionals address the pressing needs of disadvantaged teens and become valued partners in their lives. We respond immediately, confidentially and for free to teens haunted by issues such as pregnancy, depression, abuse and violence. Our effective intervention reduces the enormous long-term human, economic, and social costs of adolescent problems.
Last Update: June 9, 2014
The Mount Sinai Alzheimer's Disease Research Center (ADRC) is a nationally renowned center funded by the National Institute on Aging. The mission of the center is to provide expertise in basic and clinical research for investigators both within and beyond Mount Sinai community. The ADRC is made up of five cores and three projects.
- Administrative Core: Organizes the resources of the ADRC. Through the many national and international collaborations we can provide guidance on available data sets, tissue and cell repositories and funding opportunities. We also offer small pilot awards.
- Clinical Core: Conducts clinical, neuropsychological, genetic, biomarker and diagnostic characterization of a clinical cohort. The core cohort is available for research studies and the core faculty can provide expertise in developing evaluations for other settings and studies.
- Clinical Core Satellite: Conducts outreach and recruitment activities in our urban, minority community to accomplish enrollment of a diverse population to our clinical core. These participants receive the same clinical, neuropsychological, genetic, biomarker and diagnostic characterization. The core cohort is available for research studies and the core faculty can provide expertise in developing evaluations for other settings and studies.
- Data Core: Oversees the data collection and transmission of our data to a national data base and can provide consultation for study design and statistical analysis for this and associated projects.
- Neuropathology Core: Conduct neuropathological analysis from postmortem brain tissue specimens from persons with Alzheimer’s disease and comparison groups. Core personnel are available to advise investigators on brain region and case selection applicable to specific hypotheses. Data on select quantitative neuropathologic variables relevant to Alzheimer’s disease is provided to investigators as applicable.
- Education & Information Transfer Core: Provides community outreach, education and training including memory improvement classes and memory screenings. The core also offers physician and healthcare trainee education about dementia. The Core is also available to offer research training as regards the use of cognitive testing in research.
Last Update: May 22, 2014
The Brain Injury Research Center of Mount Sinai (BIRC-MS) conducts cutting-edge research, with a primary focus on addressing the challenges of living with traumatic brain injury, or TBI. In several recent studies, we have evaluated the effectiveness of interventions on the cognitive, emotional and behavioral functioning of people with brain injuries. We are also involved in several studies and outreach activities aimed at better identifying people with “hidden” brain injuries – where people have disabilities due to a brain injury, but are unaware of the causal link between an injury to the brain they experienced and current problems in daily life. Our research, conducted since 1987, has greatly expanded the knowledge base with respect to long-term challenges that people with TBI face, as well as approaches to leading better lives after injury.
A major part of BIRC-MS activity is sharing research results with others through outreach to the field, sharing information with people with disabilities and their families, training future researchers and taking actions to affect policy. It does this primarily through Federal grants, including the New York TBI Model System and the Mount Sinai Injury Control Research Center, as well as a multi-center grant entitled Neuropathology of Chronic Traumatic Encephalopathy (CTE) and Late Effects of Traumatic Brain Injury (TBI): Toward In-Vivo Diagnostics.
The first of these programs is funded by the National Institute on Disability and Rehabilitation Research, the second by the Centers for Disease Control and Prevention, and the third through the Foundation for the National Institutes of Health and the National Institute on Neurological Diseases and Stroke. BIRC-MS activities are also supported through the generosity of the John Blair Haldeman Endowed Fund.
Last Update: September 24, 2015
The Mount Sinai Center for Biostatistics promotes translational and clinical research at the Mount Sinai Health System by offering state-of-the-art statistical expertise in a wide variety of areas including design of clinical trials, biomarker discovery and validation, risk assessment, Bayesian methods, statistical genetics and others; and by developing novel methodological approaches. The Center’s internationally recognized faculty is committed to developing novel methodological approaches, and enhancing education through formal medical school and graduate school curricula, and mentoring of post‐doctoral fellows and junior faculty.
The Center, located within the Department of Population Health Science and Policy, collaborates closely with clinical colleagues to foster the growing research agendas. In addition to thematic long‐term collaborations, the Center’s faculty provides statistical consultations.
For more information, contact Emilia Bagiella, PhD.
Last Update: October 6, 2015
The mission of the Center for Health Equity and Community Engaged Research at Icahn School of Medicine is to improve the health and health care of underserved populations. The Center is dedicated to identifying causes of disparities in health and healthcare among underserved populations, creating and tailoring interventions and community-inspired sustainable programs to target those underlying causes, and devising innovative strategies to disseminate health messages to improve the health of minority communities. The Center is a nidus for researchers across Mount Sinai interested in health equity and community-engaged research and provides infrastructure to support their work and foster collaborations.
The Center includes a wide research portfolio ranging from programs in cancer (breast, prostate, ovarian), metabolic disease (diabetes, obesity), maternal and child health (postpartum depression, infant and maternal mortality and morbidity, postpartum care), cardiovascular disease (hypertension, heart failure and stroke), emergency medicine and pediatrics. Our multi-disciplinary faculty members also have expertise in clinical trial development, multi-site and community-based interventions, subject recruitment and retention, quality of care interventions, quality improvement, multi-method (qualitative-quantitative), and health policy research. Investigators have conducted this work through robust inter-departmental, inter-institutional and community-academic collaborations, disseminated the work through publications and high profile presentations, served on important national committees and study sections, and used the findings to inform and influence health policy. Researchers now are funded through an expanding number of federal grants, have been awarded two health disparities center grants, through the NIH and the CDC, and lead one of the 5 Centers of Mount Sinai’s Clinical and Translational Science Award, to further build our community engagement and research capacity.
Last update: September 24, 2015
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Health System is one of the most comprehensive programs in the United States focusing on treatment for and research into multiple sclerosis. Close collaboration among researchers and clinicians results in the rapid translation of new discoveries into more effective treatments, giving patients the widest possible range of options.
The Center was established to combat these hardships and provide the most comprehensive MS-related patient care and research in New York City. The hallmark of this innovative Center is its multidisciplinary approach to MS, integrating a broad base of talented physicians and scientists, all of whom have a vested interest in understanding the cause and overcoming the consequences of this devastating condition. The first of its kind in New York City, the Dickinson Center provides a holistic approach to disease management, including state-of-the-art programs in diagnostics, management, experimental therapeutics and basic research.
Patient Care: The Dickinson Center is devoted to enhancing quality of life for MS sufferers. We offer our patients 1) comprehensive, centralized care, including diagnosis, disease management, rehabilitation, and support services, 2) access to the latest and most promising research advances and 3) the opportunity to participate in trials of new therapeutic agents. Since the Dickinson Center was established in 2000, the number of patients we have seen per year has increased to over 5,000. The Center is well equipped with state-of-the art medical technology and allows us to meet our goal of offering MS patients a broad range of services in a single location.
Clinical Research: The MS Center participates in many clinical research protocols of new and novel therapeutics, developed in house and in partnership with colleagues, including NIH and the National MS Society. The Center staff includes clinical trial coordinators and monitors.
Basic Science: The development of newer and more effective therapies can be accomplished only through research that provides new levels of insight into the nature of MS. The Center seeks to bolster basic research efforts that may lead to new treatments and ultimately a cure for MS, such as neurodegeneration, glial cell biology, transplantation, stem cells and neuroimmunology. Under the direction of internationally acclaimed neuroscientists, Gareth John, PhD, Patrizia Casaccia,MD, PhD, Matilde Ingles, MD, PhD and James Sumowski, PhD, the Dickinson Center has developed a leading-edge basic science research program that has been focused on the myelin sheath and glial-cell biology, biomarker development and more recently on myelin repair and regeneration.
Last Updated: September 25, 2015
The Selikoff Center for Occupational Health at the Icahn School of Medicine at Mount Sinai provides comprehensive diagnostic and treatment services to workers suffering from occupational diseases. The Center's staff of industrial hygienists, ergonomists, and other occupational health professionals offers health and safety education and preventive services to patients, unions, employers, and other groups. The Center's physicians are board-certified in occupational and environmental medicine or are specifically trained in the diagnosis and treatment of occupational illnesses and injuries.
The Selikoff Center is a founding member of the Occupational Health Clinic Network, a long-standing state-funded network that offers services to injured and ill workers throughout New York State. The Center provides these services within the New York City and Lower Hudson Valley regions at four clinical centers located in Manhattan, Staten Island, Monroe, and Yonkers.
As the site of Mount Sinai's World Trade Center Health Program (WTCHP) Clinical Center of Excellence (CCE), the Selikoff Center continues to provide medical monitoring and treatment services to workers and volunteers who were involved in the rescue, recovery, and cleanup efforts after the attacks on September 11, 2001. These workers were exposed to many toxins at the World Trade Center site and have developed medical and mental health conditions related to their exposure. Mount Sinai's CCE is the largest of the WTCHP Clinical Centers of Excellence with a responder population exceeding 22,000 patients.
The Selikoff Center is located in the Division of Occupational and Environment Medicine, Department of Preventive Medicine, and is named after Irving J. Selikoff, MD, a physician known for his seminal research on asbestos-related disease and his tireless advocacy on behalf of workers.
Last Updated: June 23, 2016
The Center for Research on Influenza Pathogenesis (CRIP) is one of five Centers of Excellence for Influenza Research and Surveillance funded by the National Institute of Allergy and Infectious Diseases (NIAID). Influenza viruses are important human pathogens, infecting up to 500 million people annually worldwide, with the most severe pandemic leading to an estimated 40 million fatalities.
CRIP comprises a domestic and international animal influenza virus surveillance network combined with research on pathogenesis and host response. CRIP brings together experts from diverse fields including virology, immunology, molecular biology, veterinary medicine, ornithology and bioinformatics including several leaders in influenza virus research. The CRIP surveillance network spans all continents, allowing worldwide sampling and isolation of animal and human influenza viruses and early detection of emerging viruses that may cause pandemic threats. Through its research program, scientists at CRIP are dedicated to understanding influenza virus animal reservoirs, evolution, transmission and adaptation to humans as well as pathogenesis, evasion of immunity, and induction of host and vaccine responses.
Last Update: May 13, 2014
Division of ADHD and Learning Disorders
The Division of ADHD and Learning Disorders at Mount Sinai is dedicated to transforming world-class scientific research into the finest quality care for children, adolescents, and adults with ADHD, learning disorders and related neurodevelopmental conditions. The Division brings together an internationally recognized interdisciplinary clinical/research team to study key questions related to the developmental neurobiology, psychopathology, pathophysiology and treatment of ADHD, Learning Disabilities and related conditions - linking evidence-based pharmacologic and psychosocial treatments with state-of-the-art research approaches using neuroimaging and genetics. The guiding principle of the Division is to ensure that advances in the scientific basis of ADHD, learning disorders and their treatment inform clinical care delivery.
The team of expert clinicians is dedicated to improving clinical care for children, adolescents, and adults with ADHD, and children and adolescents with Learning Disabilities and related problems – consistent with the recognition that for many people, the symptoms and/or sequellae of ADHD and learning disorders persist across the lifespan. The Division’s clinical program offers psychiatric, neuropsychological and psychoeducational evaluation, behavioral and cognitive-behavioral therapies, school consultation, and medication treatment. Psychosocial interventions include organizational skills training for school age children, parent behavior management training, ADHD skills training programs for teens and adults, as well as individual psychotherapy for children and adults. Patients come from both the tri-state metropolitan New York area and other locations across the United States and around the world.
The ADHD Clinical-Translational Research Program aims to better understand the neurobiological basis of ADHD pathophysiology and treatment, and more specifically, how different treatments for ADHD bring-about clinical improvement. The program offers clinical trials of existing and novel treatments, and conducts studies which utilize brain imaging and genetic techniques in conjunction with treatment. State-of-the-art expertise in functional neuroimaging, pharmacogenomic and neuropsychological assessment converge to produce multi-faceted approaches to the study of ADHD and related disorders which transcend the boundaries between basic science and clinical treatment. The ultimate goal of this research is to provide the scientific basis for an individualized approach to diagnosis and treatment selection, in keeping with Mount Sinai’s emphasis on personalized medicine.
Visit the Center of Excellence in ADHD and Related Disorders or contact Jeffrey Newcorn for more information.
Last Update: September 24, 2015
The Children's Environmental Health Center (CEHC) conducts groundbreaking research to identify the environmental causes of childhood diseases and translates research findings into solutions that protect children's health. The Center provides support and guidance to the Department of Preventive Medicine at the Icahn School of Medicine at Mount Sinai by supporting promising research initiatives and sustaining programs to educate the next generation of medical students and pediatricians about preventable environmental hazards.
Last Update: October 9, 2015
The mission of the Mount Sinai Fibrosis Program is to create a unique, multidisciplinary program that will uncover therapeutic targets and establish novel, effective antifibrotic therapies to improve the health of patients with chronic fibrotic disorders. The overall strategy of the Program is to recruit or exploit existing expertise across the spectrum of diseases affected by fibrosis, working together to identify therapeutic targets, screen for novel drugs, and test promising agents in pre-clinical models and clinical trials.
Fibrosis, or scarring, refers to the accumulation of extracellular matrix (e.g., collagen, proteoglycans and glycoproteins) in response to chronic tissue injury. Fibrosis can involve virtually all tissues, affects hundreds of millions worldwide, and is estimated to account for ~ 45% of all deaths in the industrialized world. Those organs most commonly affected include liver (cirrhosis), lung (idiopathic pulmonary fibrosis), kidney (nephrosclerosis and tubulointerstitial fibrosis), heart (myocardial fibrosis), arteries (atherosclerosis), bone marrow (myelofibrosis), ovaries/uterus (endometriosis and fibroids) and skin (scleroderma). The past three decades have witnessed explosive growth in our understanding of the mechanisms of fibrosis, which has generated a comprehensive framework for understanding fibrotic diseases. These advances have also unearthed dozens of potential antifibrotic drug targets and spawned broad interest in the pharmaceutical and biotech sectors to develop antifibrotic drugs. While these advances are substantial, there are only two drugs approved yet as an antifibrotic therapy; however www.clinicaltrials.gov currently lists over 1600 ongoing or planned trials in fibrosis. Mount Sinai is committing to becoming the world’s leader in this rapidly expanding discipline of fibrosis pathogenesis and treatment.
The unique activities of the Program include:
- A dynamic, interactive and translational-oriented culture of scientific innovation and collaboration.
- Capacity for analysis of antifibrotic drugs in culture and animal models of tissue injury
- Access to small molecule and siRNA libraries and monoclonal antibody development to identify novel therapeutics and diagnostics
- World-class strength in genomics, bio-banking, drug discovery and translational medicine that will complement the Program’s goals of drug discovery and personalized therapies.
- Unique patient cohorts unparalleled in size or associated scientific and clinical expertise, including those with pulmonary fibrosis, cirrhosis, myelofibrosis, cardiac fibrosis and end-stage renal disease.
- Dynamic, internationally recognized leadership in fibrotic diseases.
- Unparalleled visibility of fibrosis research within Mount Sinai among pharmaceutical and biotechnology companies.
The International Center for Health Outcomes and Innovation Research (InCHOIR) is an interdisciplinary Data and Clinical Coordinating Center (DCC) in the Department of Population Health Science and Policy at Mount Sinai School of Medicine. Since its inception in 1995, one of InCHOIR’s core missions has been the design, conduct, and analysis of multi-center trials and observational studies. Over the past 7 years, the Center was awarded over $80M in clinical research funding. The core faculty and staff of 62 have expertise in clinical trial operations, biostatistics, clinical epidemiology, health economics, decision analysis, quality of life, and health policy analysis.
InCHOIR provides a coordinating center infrastructure for multi-center clinical trials and observational studies, including design, regulatory expertise and management, endpoint and event adjudication and DSMB management, data management, and FDA-compliant web-based electronic data capture systems development and implementation. The Center’s analytical expertise includes survival analysis, analysis of composite endpoints (such as MACCE), development and validation of risk scores, quality of life and economic analyses, and the analysis of imaging, and biomarker data. The Center is actively contributing to the methodology of design and analysis of clinical trials, including composite endpoints, multiple endpoints, combining information from randomized and non-randomized sources (using both classical and Bayesian methods), and adaptive trial designs. The Center has also been actively involved in using Bayesian methods to interpret the uncertainty associated with cost-effectiveness ratios and adapting the use of longitudinal methods for analyzing quality of life. The Center is committed to sustaining a high level of communication among investigators, achieving enrollment targets, ensuring high quality data, and participating in the analysis and dissemination of results.
Selected NIH-funded projects from InCHOIR’s research portfolio include the NHLBI-supported REMATCH trial (design, conduct and analysis of the 22 US clinical center trial); DCC for an NHLBI Specialized Clinical Center of Research (SCCOR) grant to elucidate and modulate the biology of the interface between implanted mechanical circulatory support devices and patients with heart failure; the ongoing NINDS-supported ARUBA Trial (66 sites across Europe, the U.S, Canada, South America, and Asia); and the DCC for the ongoing NHLBI-supported Cardiothoracic Surgical Trials Network (with 34 leading cardiac surgery centers). The industry supported research portfolio includes the design, conduct and analysis of a number of FDA-approved trials with newer generations of continuous flow left ventricular assist device (LVADs).
The Health Outcomes Core within InCHOIR is equipped with an extensive library of administrative and clinical datasets and has experience in analyzing claims and survey data, including Medicare, Medicaid, University Hospital Consortium, State-wide discharge databases, NIS and NHDS. Research focuses on geographic variations, learning curves, transition of care programs, patient safety issues, and the clinical and economic impact of diagnostic and therapeutic interventions.
Contact Maryann Krai for more information.
Last Update: May 21, 2014
The mission of the Mount Sinai Obsessive Compulsive Disorders Treatment Center is to provide specialized treatment for children, adolescents and adults suffering from Obsessive Compulsive Disorder (OCD) and OC-Spectrum disorders including tics, trichotillomania, hoarding, and body dysmorphic disorder. Our highly trained clinicians offer expert consultations, comprehensive evaluations and cutting-edge treatment options for patients suffering from mild to severe OCD, as well as treatment-resistant forms of OCD.
Located within a distinguished research institution, our long-term scientific mission is to discover the underlying causes of OCD so that new therapies can be developed that will improve the quality of life for our patients. The program director and Chair of the Department of Psychiatry, Dr. Wayne K. Goodman, is a world-renowned expert in OCD who developed the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in 1986. To date, this remains the gold standard for assessing OCD symptom severity. Dr. Goodman and our team of clinicians and scientists are committed to providing excellent clinical care and advancing the scientific understanding of OCD and related disorders.
Last Update: April 5, 2012
If you are working with the Seaver Autism Center on a grant application, please email Ellen Paley for specific information related to your application.
Visit The Seaver Autism Center for Research and Treatment or email Ellen Paley for more information.
Last Update: September 24, 2015